Solid Tumor Clinical Trials in Nashville, Tennessee

25 studies are recruiting for solid tumor in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

   The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   2 in total

   Run by

   Rise Therapeutics LLC

   See if you can join NCT06398418 on ClinicalTrials.gov

2. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Nashville, Nashville, Tennessee

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

3. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

4. Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

   The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Facility, Nashville, Tennessee

   Locations

   14 in total

   Run by

   RayzeBio, Inc.

   See if you can join NCT07165132 on ClinicalTrials.gov

5. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

   AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Center, Nashville, Tennessee

   Locations

   7 in total

   Run by

   Angiex, Inc.

   See if you can join NCT06440005 on ClinicalTrials.gov

6. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Vanderbilt - Ingram Cancer Center, Nashville, Tennessee

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

7. A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

   This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   42 in total

   Run by

   Genentech, Inc.

   See if you can join NCT06619587 on ClinicalTrials.gov

8. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

9. Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

   GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tennessee Oncology, PLLC, Nashville, Tennessee

   Locations

   11 in total

   Run by

   Georgiamune Inc

   See if you can join NCT06425926 on ClinicalTrials.gov

10. SMP-3124LP in Adults With Advanced Solid Tumors

    An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    12 in total

    Run by

    Sumitomo Pharma America, Inc.

    See if you can join NCT06526819 on ClinicalTrials.gov

11. A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

    The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monothera…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI Lake Mary, Nashville, Tennessee

    Locations

    15 in total

    Run by

    PAQ Therapeutics, Inc.

    See if you can join NCT06797336 on ClinicalTrials.gov

12. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #3, Nashville, Tennessee

    Locations

    122 in total

    Run by

    Exelixis

    See if you can join NCT05176483 on ClinicalTrials.gov

13. A Study of ASP3082 in Adults With Advanced Solid Tumors

    This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Locations

    66 in total

    Run by

    Astellas Pharma Inc

    See if you can join NCT05382559 on ClinicalTrials.gov

14. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University School of Medicine, Nashville, Tennessee

    Locations

    42 in total

    Run by

    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov

15. A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

    This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    14 in total

    Run by

    Chugai Pharmaceutical

    See if you can join NCT05907980 on ClinicalTrials.gov

16. A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

    This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site-116, Nashville, Tennessee

    Locations

    17 in total

    Run by

    Biohaven Therapeutics Ltd.

    See if you can join NCT06874335 on ClinicalTrials.gov

17. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

    This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #3, Nashville, Tennessee

    Locations

    11 in total

    Run by

    Exelixis

    See if you can join NCT06952010 on ClinicalTrials.gov

18. A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

    The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer [OC], endometrial cancer [EC], non-sma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Locations

    58 in total

    Run by

    Eisai Inc.

    See if you can join NCT04300556 on ClinicalTrials.gov

19. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute (SCRI), Nashville, Tennessee

    Locations

    19 in total

    Run by

    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov

20. A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

    This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site 0196, Nashville, Tennessee

    Locations

    24 in total

    Run by

    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

    See if you can join NCT04516447 on ClinicalTrials.gov

21. A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

    This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site-107, Nashville, Tennessee

    Locations

    17 in total

    Run by

    Biohaven Therapeutics Ltd.

    See if you can join NCT06384807 on ClinicalTrials.gov

22. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

    This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

    Locations

    21 in total

    Run by

    I-Mab Biopharma US Limited

    See if you can join NCT04900818 on ClinicalTrials.gov

23. A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

    This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    15 in total

    Run by

    OnCusp Therapeutics, Inc.

    See if you can join NCT06234423 on ClinicalTrials.gov

24. FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

    The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee

    Locations

    19 in total

    Run by

    Pierre Fabre Medicament

    See if you can join NCT06669117 on ClinicalTrials.gov

25. First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

    The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expre…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI - Nashville, Nashville, Tennessee

    Locations

    26 in total

    Run by

    Corbus Pharmaceuticals Inc.

    See if you can join NCT06603844 on ClinicalTrials.gov